SCHEMBL16178737

SCHEMBL16178737

CC1CN(C(=O)Nc2ccc3ncsc3c2)CCN1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 8/20 0.44
▸ NPC1 O15118 7/20 0.44
▸ CHRM5 P08912 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ OTUD7B Q6GQQ9 1/20 0.44
▸ USP30 Q70CQ3 1/20 0.44
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ KEAP1 Q14145 2/20 0.43
▸ NFE2L2 Q16236 2/20 0.43
▸ GOT1 P17174 1/20 0.43
▸ UBE2M P61081 1/20 0.43
▸ DCUN1D1 Q96GG9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16178505 0.75 RAB9A (0.57) RAB9ANPC1ALDH1A1MAPTSMN1; SMN2
SCHEMBL8863163 0.74 LDHA (0.57) RAB9ANPC1KDM4EALDH1A1MAPT
SCHEMBL16178778 0.74 CCR2 (0.45) —
SCHEMBL7890248 0.73 POLB (0.66) RAB9ANPC1KDM4EALDH1A1CYP1A2
SCHEMBL1148015 0.73 IKBKB (0.68) RAB9ANPC1CHRM5KDM4ESMN1; SMN2
SCHEMBL16178760 0.72 SMN1; SMN2 (0.51) KDM4EALDH1A1MAPTSMN1; SMN2UBE2M
SCHEMBL17964656 0.72 PI4KB (0.73) —
SCHEMBL17964655 0.72 PI4KB (0.73) —
SCHEMBL10114638 0.72 KEAP1 (0.47) RAB9ANPC1CHRM5KDM4EALDH1A1
SCHEMBL10115991 0.72 CHRM5 (0.46) RAB9ANPC1CHRM5KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096614-B2 Therapeutically active thiazolo-pyrimidine derivatives UCB PHARMA SA (BE) 2015-08-04 — — US disclosed
US-20140315885-A1 Therapeutically Active Thiazolo-Pyrimidine Derivatives UCB PHARMA SA (BE) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315885-A1 Therapeutically Active Thiazolo-Pyrimidine Derivatives TPMT, IFNG, IRF3 RAB9A 1399/4885NPC1 1968/4885CHRM5 3604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback